Accueil/Actions/PHAT

PHAT

USD

Phathom Pharmaceuticals Inc. Common Stock

$13.250+0.330 (2.554%)

Prix en Temps Réel

Healthcare

Biotechnologie

États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché

Fondamentaux de l'Entreprise

Statistiques de Trading

Métriques de Marché

Ouverture

$12.920

Haut

$13.320

Bas

$12.310

Volume

0.84M

Fondamentaux de l'Entreprise

Capitalisation Boursière

942.6M

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

1.18M

Bourse

NMS

Devise

USD

Intervalle sur 52 Semaines

Bas $2.21Actuel $13.250Haut $17.63

Actualités Connexes

4 nov. 2025 · 13:00

GlobeNewswire

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

First patient dosed, with topline results expected in 2027pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory treatment in EoE FLORHAM PARK, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) --

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

31 oct. 2025 · 10:50

Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Phathom Pharmaceuticals, Raises Price Target to $26

HC Wainwright & Co. analyst Matthew Caufield maintains Phathom Pharmaceuticals with a Buy and raises the price target from $20 to $26.

HC Wainwright & Co. Maintains Buy on Phathom Pharmaceuticals, Raises Price Target to $26

25 oct. 2025 · 13:59

GlobeNewswire

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

Data published in the American Journal of Gastroenterology showed rapid and sustained relief of nighttime gastroesophageal reflux disease (GERD) symptoms in patients treated with VOQUEZNA, including clinically meaningful

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

23 oct. 2025 · 12:00

GlobeNewswire

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

FLORHAM PARK, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI)